450 related articles for article (PubMed ID: 8383657)
21. Therapy of soft tissue infections with piperacillin/tazobactam.
Tassler H; Cullmann W; Elhardt D
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():105-12. PubMed ID: 8383651
[TBL] [Abstract][Full Text] [Related]
22. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections.
Angerås MH; Darle N; Hamnström K; Ekelund M; Engström L; Takala J; Viste A; Holme JB
Scand J Infect Dis; 1996; 28(5):513-8. PubMed ID: 8953684
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.
Mouton Y; Leroy O; Beuscart C; Chidiac C; Senneville E; Ajana F; Lecocq P
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():87-95. PubMed ID: 8383658
[TBL] [Abstract][Full Text] [Related]
24. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.
de Groot HG; Hustinx PA; Lampe AS; Oosterwijk WM
J Antimicrob Chemother; 1993 Sep; 32(3):491-500. PubMed ID: 8262872
[TBL] [Abstract][Full Text] [Related]
25. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
26. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
[TBL] [Abstract][Full Text] [Related]
27. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
28. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
[TBL] [Abstract][Full Text] [Related]
29. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective.
Marra FO; Frighetto LO; Marra CA; Sleigh KM; Stiver HG; Bryce EA; Reynolds RP; Jewesson PJ
Ann Pharmacother; 1999 Feb; 33(2):156-62. PubMed ID: 10084409
[TBL] [Abstract][Full Text] [Related]
30. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
31. Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
Schmitt DV; Leitner E; Welte T; Lode H
Infection; 2006 Jun; 34(3):127-34. PubMed ID: 16804655
[TBL] [Abstract][Full Text] [Related]
32. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.
Ito I; Kadowaki S; Tanabe N; Haruna A; Kase M; Yasutomo Y; Tsukino M; Nakai A; Matsumoto H; Niimi A; Chin K; Ichiyama S; Mishima M
Pulm Pharmacol Ther; 2010 Oct; 23(5):403-10. PubMed ID: 20561917
[TBL] [Abstract][Full Text] [Related]
33. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF
Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparative trial of imipenem/cilastatin versus aminoglycoside plus amoxycillin plus clindamycin in the treatment of severe intra- and post-operative infections.
Cakmakci M; Stern A; Schilling J; Christen D; Roggo A; Geroulanos S
Drugs Exp Clin Res; 1993; 19(5):223-7. PubMed ID: 8174495
[TBL] [Abstract][Full Text] [Related]
36. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections.
Shyr YM; Lui WY; Su CH; Wang LS; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Aug; 56(2):102-8. PubMed ID: 7553416
[TBL] [Abstract][Full Text] [Related]
37. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
38. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study.
Norrby SR; Vandercam B; Louie T; Runde V; Norberg B; Anniko M; Andrien F; Baudrihaye M; Bow E; Burman LA
Scand J Infect Dis Suppl; 1987; 52():65-78. PubMed ID: 3331044
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
[TBL] [Abstract][Full Text] [Related]
40. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
